Organization | Kangbuk Samsung Hospital

Kangbuk Samsung Hospital Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Seoul Korea, Republic of (1968)

Organization Overview

First Clinical Trial

2008

NCT00699049

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Dong Il Park, M.D, Ph.D. | Eunah Cho, MD | Ho Cheol Shin, M.D., Ph.D. | Kangbuk Samsung Hospital | Kangbuk Samsung Hospital, Seoul, Republic of Korea | KYU-SUNG LEE | Samsun Education and Research Hospital | Samsung Medical Center, Seoul, Republic of Korea | samsung seoul medical center | Seok Jin Kim

Active Ingredients

Drugs in Phase 4 Trials (13)

acetylsalicylic acid (aspirin) (1 trial)

cilostazol (pletal) (1 trial)

clopidogrel (plavix) (1 trial)

entecavir (baraclude) (1 trial)

escherichia coli nissle 1917 (1 trial)

glimepiride (amaryl) (3 trials)

lamivudine (epivir) (1 trial)

motilitone (1 trial)

pantoprazole (protonix) (1 trial)

polyethylene glycol (1 trial)

silodosin (rapaflo) (1 trial)

sitagliptin (januvia) (4 trials)

solifenacin (vesicare) (2 trials)

Drugs in Phase 3 Trials (14)

amlodipine (norvasc) (2 trials)

anagliptin (1 trial)

desflurane (suprane) (6 trials)

evogliptin (Suganon) (1 trial)

fimasartan (kanarb) (4 trials)

human placenta hydrolysate (1 trial)

lidocaine (xylocaine) (2 trials)

lobeglitazone (1 trial)

losartan (cozaar) (1 trial)

magnesium sulfate (Tis-U-Sol) (1 trial)

pioglitazone (actos) (1 trial)

propafenone (rythmol) (1 trial)

sevoflurane (ultane) (7 trials)

valsartan (diovan) (1 trial)

Drugs in Phase 2 Trials (18)

allogeneic plx-pad cells (1 trial)

bevacizumab (avastin) (1 trial)

ceftriaxone (rocephin) (1 trial)

fludarabine (fludara) (1 trial)

gimeracil (1 trial)

mitoxantrone (novantrone) (1 trial)

moxifloxacin (avelox) (1 trial)

oteracil (1 trial)

oxaliplatin (eloxatin) (1 trial)

paclitaxel (taxol) (1 trial)

riluzole (rilutek) (1 trial)

tegafur (1 trial)

trametinib (mekinist) (1 trial)

trastuzumab (herceptin) (1 trial)

vorinostat (zolinza) (1 trial)

yh14618 (1 trial)

Drugs in Phase 1 Trials (4)

capecitabine (xeloda) (1 trial)

dapagliflozin (farxiga) (1 trial)

empagliflozin (jardiance) (1 trial)

gemigliptin (Zemiglo) (1 trial)

Drugs in Other Trials (12)

bupivacaine (Exparel) (2 trials)

dexmedetomidine (precedex) (2 trials)

glycopyrronium (robinul) (2 trials)

hydroquinone (1 trial)

midazolam (versed) (1 trial)

nefopam (Acupan) (1 trial)

pregabalin (lyrica) (1 trial)

remifentanil (ultiva) (1 trial)

remimazolam (Byfavo) (3 trials)

ropivacaine (naropin) (1 trial)

sodium chloride (1 trial)

sufentanil (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Amyotrophic Lateral Sclerosis (Phase 2)

Cholangitis (Phase 2)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Dyspepsia (Phase 4)

Essential Hypertension (Phase 3)

Fatigue (Phase 3)

Fatigue Syndrome, Chronic (Phase 3)

Genital Diseases, Female (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Hepatitis B, Chronic (Phase 4)

Hypertension (Phase 3)

Intermittent Claudication (Phase 2)

Intervertebral Disc Degeneration (Phase 2)

Liver Diseases (Phase 4)

Lymphoma (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Motor Neuron Disease (Phase 2)

Musculoskeletal Diseases (Phase 3)

Peripheral Arterial Disease (Phase 2)

Sclerosis (Phase 2)

Spinal Diseases (Phase 2)

Stomach Neoplasms (Phase 2)

Syndrome (Phase 3)

Ureteral Calculi (Phase 4)

Ureterolithiasis (Phase 4)

Urinary Bladder, Overactive (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 52
# of Trial APIs: 61